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Abstract
Background: Cancer antigen CA125 is known as a val-
uable marker for the management of ovarian cancer.
Methods: The analytical and clinical performance of
the Access OV Monitor Immunoassay System (Beck-
man Coulter) was evaluated at five different European
sites and compared with a reference system, defined
as CA125 on the Elecsys System (Roche Diagnostics).
Results: Total imprecision (%CV) of the OV Monitor
ranged between 3.1% and 8.8%, and inter-laboratory
reproducibility between 4.7% and 5.0%. Linearity
upon dilution showed a mean recovery of 100%
(SDq8.1%). Endogenous interferents had no influ-
ence on OV Monitor levels (mean recoveries: hemo-
globin 107%, bilirubin 103%, triglycerides 103%).
There was no high-dose hook effect up to 27,193
kU/L. Clinical performance investigated in sera from
1811 individuals showed a good correlation between
the Access OV Monitor and Elecsys CA125 (Rs0.982,
slopes0.921, interceptsq1.951). OV Monitor serum
levels were low in healthy individuals (ns267,
medians9.7 kU/L, 95th percentiles30.8 kU/L), higher
in individuals with various benign diseases (ns549,
medianss10.9–16.4 kU/L, 95th percentiless44.2–
355 kU/L) and even higher in individuals suffering
from various cancers (ns995, medianss12.4–445
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kU/L; 95th percentiless53.4–4664 kU/L). Optimal
diagnostic accuracy for cancer detection against the
relevant benign control group by the OV Monitor was
found for ovarian cancer warea under the curve (AUC)
0.898x. Results for the reference CA125 assay were
comparable (AUC 0.899).
Conclusions: The Access OV Monitor provides very
good methodological characteristics and demon-
strates an excellent analytical and clinical correlation
with Elecsys CA125. The best diagnostic accuracy for
the OV Monitor was found in ovarian cancer. Our
results also suggest a clinical value of the OV Monitor
in other cancers.
Clin Chem Lab Med 2008;46:588–99.
Keywords: CA125; diagnosis; method comparison;
ovarian cancer.
Introduction
Ovarian cancer is the fifth most common cause of
tumor-related death in women in the developed world
and the most lethal gynecological malignancy (1).
Unlike other tumor entities with few histological
subtypes, ovarian cancer subsummarizes a variety of
distinct tumor types, including epithelial, germ cell,
sex-cord stromal and metastatic tumors (2). Because
prognosis is best in early stages but clinical symp-
toms often appear only late, there is a great need for
parameters which improve early diagnosis of ovarian
cancer (3).
Besides progress in radiological diagnostics, serum
related markers have shown to provide valuable dif-
ferential diagnostic and prognostic information and to
be useful for the management of the disease in the
further follow-up care after the primary therapy was
applied (4–6). Among ovarian cancer serum markers,
the tumor-associated antigen CA125 has proven a
high sensitivity for cancer detection, particularly if
used in serial measurements (2, 3, 6, 7).
CA125 is an antigenic determinant found on a high-
molecular weight glycoprotein of 200–2000 kDa orig-
inally detected by the OC125 monoclonal antibody
on a human serous cystadenocarinoma cell line
AVCA433 (8). It is physiologically present in a number
of normal adult tissues derived from the coelomic epi-
thelium, as well as in cells of mesothelial origin, such
as pleural, pericardial and peritoneal cells (2, 3, 9–11).
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Recent studies indicate that CA125 has a widespread
distribution in human tissues, such as epithelia of kid-
ney, lung, stomach, gall bladder, pancreas, and colon,
as well as in malignancies of these organs (2, 9).
Despite this lack of organ specificity, CA125 has a
very high sensitivity for ovarian cancer, already in
early stages, and was supposed to be a valuable
marker for differential diagnosis of ovarian cancer
(2, 9, 12–17). Preoperative sensitivity and specificity
could be improved by combination with other cancer
antigens, such as CA15-3 and CA72-4 (14, 16). Further,
prognostic value of CA125 values was found (18, 19).
In addition, CA125 mirrors the recurrence of disease
in blood accurately and frequently with a lead time of
several months prior to radiological detectable tumor
manifestations (2, 9, 20–22), Finally, the therapy effi-
cacy can be monitored effectively by the course of
CA125, if interpreted by experts (2, 9, 20–22).
In the present study, a new assay for detection of
CA125 antigen was evaluated for its analytical and
clinical performance, and compared with an estab-
lished reference method. This Access OV Monitor
assay is applied on the UniCel DxI 800 Immunoassay
System (Beckman Coulter Eurocenter S.A., Nyon,
Switzerland) and uses OVK 95 as monoclonal tracer
antibody, which recognizes practically the same epi-
tope as the Centocor OC125 antibody (Centocor Inc.,
Horsham, PA, USA) (23), and OV185 as monoclonal
capture antibody, which detects a similar epitope as
the Centocor M11 antibody (23). As most of the cur-
rently available assays are based on the original Cen-
tocor antibody, it is challenging to compare the
clinical relevance of the new assay using an alterna-
tive antibody, which in consequence has led to the
new name ‘‘Access OV Monitor assay’’.
The present evaluation was performed as a Euro-
pean multicenter trial including five sites in various
countries.
Materials and methods
Assay procedure
Access OV Monitor (CA125 antigen) assay on the UniCel
DxI 800 Immunoassay System (Beckman Coulter) The
Access OV Monitor assay is a paramagnetic particle, two-
site immunoenzymatic (‘‘sandwich’’), chemiluminescent
immunoassay for the quantitative determination of CA125
antigen levels in human serum and plasma using the Access
Immunoassay Systems. A sample is added to a reaction ves-
sel along with paramagnetic particles coated with polyclonal
goat anti-biotin antibody, mouse monoclonal-biotin conju-
gate and a buffered protein solution. After incubation in a
reaction vessel, separation in a magnetic field and washing
remove materials not bound to the solid phase. A monoclo-
nal-alkaline phosphatase conjugate is then added. After incu-
bation in a reaction vessel, materials bound to the solid
phase are held in a magnetic field, while unbound materials
are washed away. Then, the chemiluminescent substrate
Lumi-Phos 530 is added to the vessel and light generated by
the reaction is measured with a luminometer. The light pro-
duction is directly proportional to the concentration of CA125
antigen in the sample. The amount of analyte in the sample
is determined from a stored, multi-point calibration curve.
Samples can be accurately measured within the analytic
range of the lower limit of detection and the highest calibra-
tor value (approximately 0.5–5000 kU/L).
For calibration, Access OV Monitor Calibrators (Cat. No.
386358: S0–S5, 2.5 mL/vial) were used. The Access OV Mon-
itor Calibrators are provided at six levels – zero and approx-
imately 25, 100, 500, 2000 and 5000 kU/L. Controls, Bio-Rad
Lyphochek Tumor Marker Controls (Cat. No. 580 Bilevel,
6=2 mL; Bio-Rad Laboratories, Munich, Germany), were run
in duplicates every day of the study.
CA125 assay on Elecsys 2010 Immunology System (Roche
Diagnostics GmbH) The CA125 assay is an electrochemo-
luminescence immunoassay for the quantitative determina-
tion of CA125 antigen levels in human serum and plasma
using the Elecsys 2010/1010 and Modular Analytics E170
Immunology Systems (Roche Diagnostics, Penzberg, Ger-
many). The assay is based on a sandwich principle with the
monoclonal antibodies OC125 and M11: 20 mL of sample, a
biotinylated monoclonal CA125-specific antibody, and the
monoclonal antibody labeled with a ruthenium complex
form a sandwich complex. After addition of streptavidin-
coated microparticles, the complex becomes bound to the
solid phase via interaction of biotin and streptavidin. The
reaction mixture is aspirated into the measuring cell, where
the microparticles are magnetically captured onto the sur-
face of the electrode. Unbound substances are then removed
with ProCell buffer. Application of a voltage to the electrode
then induces chemiluminescent emission that is measured
by a photomultiplier tube. Results are determined via a cal-
ibration curve which is instrument-specifically generated by
two-point calibration and a master curve provided by the
manufacturer via the reagent pack barcode.
Samples can be accurately measured within the analytic
range of 0.5–5000 kU/L.
For calibration, Elecsys CA125 CalSet (Cat. No. 11776240,
for 4=1 mL) was used. Controls, Elecsys PreciControl Tumor
Markers 1 and 2 (Cat. No. 11776452, 2=3 mL), were run in
duplicates every day of the study.
Analytical evaluation
The analytical performance of the Access OV Monitor assay
was evaluated by all five centers in parallel, in particular
imprecision, inter-laboratory reproducibility, minimum
detectable concentration and linearity upon dilution. The
influence of endogenous interferents and high-dose hook
effect was tested in the laboratories of Munich, Barcelona
and Aachen; interferences of sample type and sample stor-
age were only tested in Munich.
Imprecision Two controls (Bio-Rad) and three human
serum pools prepared by each center, including a low, medi-
um and high concentration pool, were tested in triplicate,
with two runs per day for at least 10 days according to the
guidelines of the CLSI (Clinical and Laboratory Standards
Institute, formerly NCCLS; document NCCLS-EP5-A). Data
analysis included calculation of within-run and total impre-
cision and was performed by Acomed Statistics, Leipzig,
Germany.
Inter-laboratory reproducibility Inter-laboratory reproduci-
bility was evaluated using the two controls across the five
evaluation sites.
Minimum detectable concentration The minimum detect-
able concentration was defined as the OV Monitor concen-
tration corresponding to a signal two standard deviations
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above the main value of 10 replicates of the S0 calibrator
tested on each of 3 days.
Linearity upon dilution A total of 27 samples, with five of
them above the assay dynamic range ()5000 kU/L) and 16
of them between 1000 and 5000 kU/L, were diluted with the
appropriate Access OV Monitor diluent to obtain a minimum
of four dilutions within the assay dynamic range. Dilutions
were prepared separately in one to two steps using calibrat-
ed pipettes and were carried out in four replicates. Recov-
eries were calculated with respect to the highest concen-
tration in the dynamic range.
Sample type interference Samples were obtained from 10
patients with unsuspicious laboratory findings, one serum in
tubes with kaolin, one lithium-heparinate plasma, one EDTA
plasma and one citrate plasma. Sample type interference
was tested in duplicates. Recoveries were calculated with
respect to the concentration in the serum sample.
Sample storage interference Samples from seven of these
patients were measured natively and after storage at 48C and
–208C for 1 day. Both storage modalities were compared
with the native measurements.
Further, serum and lithium-heparinate plasma samples of
the 10 patients were stored at –208C for 6 months and meas-
urements were compared with the original –208C data to test
the long-term stability.
Endogenous interferents The influence of bilirubin, hemo-
globin and triglycerides was tested on a human serum pool
with high CA125 concentrations. The serum pool was diluted
with a serum containing high bilirubin concentrations
()0.062 mmol/L), with a serum with high hemoglobin (ca.
0.855 mmol/L; normal serum spiked with hemolyzed blood
sample) and with a serum with high triglyceride concentra-
tion ()0.006 mmol/L). These test solutions were tested with
the Access OV Monitor assay and compared to the control
solutions obtained from the same pool diluted in the same
way with the Sample Diluent A (Catalog Number 81908)
instead of the interfering substance. Each test solution and
each control solution were assayed 10 times in constantly
decreasing proportions. Recoveries were calculated with
respect to the concentration of the undiluted serum pool.
Additionally, 10 samples with high known rheumatoid factor
concentration were tested in duplicate.
High-dose hook effect Serial 10-fold dilutions of two differ-
ent samples with very high CA125 concentrations above
20,000 kU/L were tested. Recoveries were calculated with
respect to the highest concentration in the dynamic range.
Clinical performance
The clinical performance of the Access OV Monitor assay
was evaluated by two sites (Munich and Barcelona). All clin-
ical samples were sent to the Institute of Clinical Chemistry
of the University Hospital Munich, to be tested using the
Access OV Monitor assay on the UniCel DxI 800 Immuno-
assay System (Beckman Coulter) and compared to the
reference CA125 assay on the Elecsys 2010 Immunology
System (Roche Diagnostics).
Healthy individuals The normal reference interval for the
OV Monitor was established from 267 samples, including
113 sera from men and 154 sera from non-pregnant women.
The subject inclusion/exclusion criteria were as follows:
• normal, apparently healthy subjects (evaluated clinically
and by clinical chemistry parameters),
• adults older than 18 years were tested,
• no personal history of cancer disease, renal failure or
liver disease.
Age and sex were mandatory for all samples enrolled.
Samples with hemolysis, bilirubin or lipemia were excluded.
Individuals with benign diseases OV Monitor results were
determined in a total of 549 individuals diagnosed with
benign diseases, among them 109 benign gynecological dis-
eases (ovarian cysts, endometriosis, uterine leiomyoma,
etc.), 148 benign breast diseases, 155 benign gastrointestinal
diseases (ulcerous colitis, Crohn’s disease, liver cirrhosis,
hepatitis, pancreatitis, cholelithiasis, etc.), 44 benign lung
diseases (tuberculosis, sarcoidosis, pneumonia, etc.), 66
benign urological diseases (nephrolithiasis, renal failure,
etc.) and 27 other benign diseases, and compared with the
reference system.
Individuals with malignant diseases OV Monitor results
were determined in a total of 995 individuals diagnosedwith
cancer diseases and compared with the reference system.
The cancer diseases included 81 ovarian cancers, 416 breast
cancers, 57 other gynecological cancers, 62 pancreatic can-
cers, 26 gastric cancers, 58 hepatocellular cancers, 113 colo-
rectal cancers, 82 lung cancers, 57 urological cancers
(bladder and kidneys) and 43 prostate cancers.
All samples were obtained from patients with active dis-
ease, typically before surgery as first treatment modality, or
in some cases at time of recurrent disease.
Statistical analysis
The OV Monitor assay and reference method were compared
using regression equations according to Passing and Bablok.
Normalized differences from mean values were calculated
according to Bland and Altman.
In healthy individuals, the frequency distribution for the
OV Monitor and reference method was defined including
25th percentile, median, mean and upper reference limit
(URL) of a normal population at 95th, 97.5th and 99th
percentiles.
In all studied groups, distribution of the OV Monitor and
reference method concentrations were presented graphical-
ly, as well as statistically (median, range, 95th percentile).
The analysis of the sensitivity/specificity for ovarian cancer
included receiver operator characteristics (ROC) curves,
using benign gynecological diseases as the control group.
Similarly, ROC curves were established for breast cancer vs.
benign breast diseases, lung cancer vs. benign lung dis-
eases, and colorectal cancer vs. benign gastrointestinal dis-
eases. Further, at 95% specificity against the respective
benign control group, the sensitivity for each cancer type
was calculated, and also the area under the curve (AUC)
of the corresponding ROC curves with the corresponding
95% confidence interval.
Results
Analytical evaluation
Imprecision Within-run imprecision of the low con-
trol (26.4–30.2 kU/L) ranged in the various centers
between 2.1% and 3.4%, and of the high control
Bereitgestellt von | Universitaetsbibliothek der LMU Muenchen
Angemeldet | 129.187.254.47
Heruntergeladen am | 18.11.13 10:39
Holdenrieder et al.: Analytical and clinical evaluation of OV Monitor assay 591
Article in press - uncorrected proof
Figure 1 Linearity upon dilution.
Samples with high OV Monitor levels were diluted by one to
two steps and recoveries were calculated for various dilution
steps.
(118.2–127.2 kU/L) between 1.9% and 2.8%. Within-
run imprecision of the low serum pools (ranging from
6.3 to 46.7 kU/L) was between 2.4% and 3.2%, of the
medium serum pools (ranging from 46.1 to 345 kU/L)
between 2.0% and 2.7%, and of the high serum pools
(ranging from 390 to 1939 kU/L) between 2.2% and
2.8%.
Total imprecision of the low control (26.4–30.2
kU/L) ranged in the various centers between 3.7% and
5.9%, and of the high control (118.2–127.2 kU/L)
between 3.7% and 5.8%. Total imprecision of the low
serum pools (6.3–46.7 kU/L) was between 3.6% and
8.8%, of the medium serum pools (46.1–345 kU/L)
between 3.0% and 7.9%, and of the serum pools
(390–1939 kU/L) between 4.2% and 6.0%.
Inter-laboratory reproducibility Inter-laboratory impre-
cision of the low control (26.4–30.2 kU/L) was found to
be 5.0%, and of the high control (118.2–127.2 kU/L)
4.7%.
Minimum detectable concentration The minimum
detectable concentration was found to be -2.0 kU/L
in all centers. All these results are in the very low
range and have no clinical relevance.
Linearity upon dilution In total, 27 samples were
investigated on linearity upon dilution. Dilutions were
performed with the appropriate Access OV Monitor
diluent in one to two steps, down to the low value
range (-30 kU/L), with a minimum of four dilutions
within the assay dynamic range. Mean recovery of all
dilutions in all centers was 100%, with a standard
deviation of 8.1% (minimum 84.0%, maximum 138%)
(Figure 1).
Sample type interference Samples from 10 patients
with unsuspicious laboratory findings were tested on
sample type interference. OV Monitor measurements
in kaolin serum and lithium-heparinate plasma were
very comparable. Mean recovery in heparinate plas-
ma was 101%, with a standard deviation of 3.7% (min-
imum 95.6%, maximum 108%). OV Monitor values in
EDTA plasma and citrate plasma were very compar-
able and lower than OV Monitor values in serum. For
EDTA plasma, mean recovery was 91.8%, with a stan-
dard deviation of 7.0% (minimum 83.3%, maximum
106%). For citrate plasma, mean recovery was 81.0%,
with a standard deviation of 6.4% (minimum 72.1%,
maximum 90.9%).
Sample storage interference Samples from seven of
these patients were measured natively, after storage
at 48C and at –208C for 1 day. Both storage conditions
tested did not affect the OV Monitor values. After stor-
age at 48C, mean recovery was 99.3%, with a standard
deviation of 6.3% (minimum 92.4%, maximum 107%).
After storage at –208C, mean recovery was 98.4%,
with a standard deviation of 4.5% (minimum 94.0%,
maximum 105%).
In addition, serum and lithium-heparinate plasma
samples of the 10 patients were stored at –208C for
6 months and measurements were compared with the
original –208C data to test the long-term stability.
Again, storage had no influence on marker levels.
When serum was stored at –208C for 6 months, mean
recovery was 93.6%, with a standard deviation of
6.3% (minimum 86.1%, maximum 104%). When lithi-
um-heparinate plasma was stored at –208C for
6 months, mean recovery was 93.2%, with a standard
deviation of 10.4% (minimum 71.5%, maximum
108%).
Endogenous interferents The potentially confound-
ing impact of endogenous interferents, such as hemo-
globin, bilirubin and triglycerides, was tested at two
centers. Stepwise dilution of a serum pool having
high CA125 levels with a serum sample with high con-
centrations of the relevant interferent and, alternative-
ly, with sample diluent which was free of any
contamination showed that neither interferent had
any influence on OV Marker levels.
Dilution with hemoglobin-spiked serum resulted in
a mean recovery of 107%, with a standard deviation
of 11.4% (minimum 95.9%, maximum 144%). There
was no trend of continuously changing OV Monitor
values when increasing amounts of hemoglobin were
added (Figure 2).
Dilution with bilirubin-rich serum showed a mean
recovery of 103%, with a standard deviation of 13.0%
(minimum 88.1%, maximum 152%). There was no
trend of continuously changing OV Monitor values
when increasing amounts of bilirubin were added
(Figure 2).
In the dilution series with triglyceride-rich serum,
mean recovery was 103%, with a standard deviation
of 9.2% (minimum 93.2%, maximum 133%). There
was no trend of continuously changing OV Monitor
values when increasing amounts of triglycerides were
added (Figure 2).
Rheumatoid factor In total, 14 serum samples with
high rheumatoid factor concentrations (mean
209.4 kU/L, standard deviation 298.0 kU/L, minimum
26.7 kU/L, maximum 1131 kU/L) were tested on a
potential confounding effect on OV Monitor values.
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Figure 2 Influence of endogenous interferences.
Samples were spiked with various concentrations of hemo-
globin (), bilirubin (m) and triglycerides (d) and recoveries
of OV Monitor levels were calculated for various dilution
steps.
However, all OV Monitor levels were very low in the
range of healthy individuals. Mean value was 11.8
kU/L, with a standard deviation of 4.6 kU/L (minimum
5.7 kU/L, maximum 19.1 kU/L).
High-dose hook effect In total, two serum samples
with extremely high CA125 levels (24,950 and
27,193 kU/L) were tested in dilution series on a poten-
tial high-dose hook effect. In all samples a linear dilu-
tion response was observed with a mean recovery of
103% and a standard deviation of 8.6% (minimum
95.1%, maximum 122%).
Clinical performance
Method comparison Comparison of the Access OV
Monitor (CA125 antigen) assay on the UniCel DxI 800
Immunoassay System and the CA125 assay on the
Elecsys 2010 Immunology System, calculated on all
serum samples (ns1811), yielded a correlation coef-
ficient of Rs0.982, with a slope of 0.921 and an inter-
cept of q1.951.
A large number of samples (1751 out of 1811) were
found to have values up to 500 kU/L. For this group,
an excellent correlation was still found. The coeffi-
cient of correlation was Rs0.937, with a slope of
0.946 and an intercept of q1.660 kU/L. Values up to
100 kU/L were found in 1600 out of 1811 samples. For
this clinically relevant group, a similarly good corre-
lation was found. The coefficient of correlation was
Rs0.939, with a slope of 0.992 and an intercept of
q1.208 kU/L (Figure 3).
Healthy individuals For the Access OV Monitor, the
95th percentile URL of a healthy population (ns267)
was found at 30.8 kU/L. The value distribution ranged
from 1.3 to 175 kU/L. Mean was at 13.2 kU/L, median
at 9.7 kU/L. The 25th percentile was calculated at 6.8
kU/L, 97.5th percentile at 36.6 kU/L and 99th percentile
at 55.8 kU/L. Females (median at 9.4 kU/L, 95th per-
centile at 27.2 kU/L) and males (median at 11.1 kU/L,
95th percentile at 32.4 kU/L) had a similar value dis-
tribution. Both methods showed a very comparable
distribution and a good correlation (Rs0.949, slope
1.026, intercept of q0.415) (Figure 4, Table 1).
Individuals with benign diseases Of 549 individuals
diagnosed with benign diseases, patients with benign
gastrointestinal diseases showed the highest levels
for the Access OV Monitor (median at 15.4 kU/L, 95th
percentile at 355 kU/L). The lowest levels were found
in benign breast diseases (median at 12.0 kU/L, 95th
percentile at 44.2 kU/L), which were in the range of
healthy individuals. For all benign diseases, both
methods showed comparable results and a good cor-
relation (Rs0.903, slope 0.959, intercept of q1.602).
Details of value distribution are listed in Table 1 and
Figure 4.
Individuals with malignant diseases Of 995 individ-
uals diagnosed with malignant diseases, patients with
ovarian cancer showed the highest levels for the
Access OV Monitor (median at 445 kU/L, 95th percen-
tile at 4664 kU/L), with maximum levels of more than
15,000 kU/L. Some strongly elevated values were
found in single individuals with gynecological, breast,
hepatocellular, pancreatic, colorectal and lung can-
cers too, but median and 95th percentiles were con-
siderably lower than in ovarian cancer. Lower values
with maximum levels -200 kU/L were observed in
gastric, urological and prostate cancer. In general,
results of both methods were very comparable and a
good correlation was found (Rs0.943, slope 0.908,
intercept of q2.384). Details of value distribution are
listed in Table 1 and Figure 5.
The frequency distribution of OV Monitor values
showed that most of the samples of healthy individ-
uals, and individuals with various benign diseases
and individuals with malignant diseases without ovar-
ian cancer had very low OV Monitor levels not only
in the reference range -35 kU/L but even below
15 kU/L (Figure 6). In contrast, only a few individuals
with ovarian cancer with or without distant metasta-
ses had such low OV Monitor concentrations. This
non-release of OV Monitor is, thus, particularly impor-
tant to estimate the probability of not having ovarian
cancer if there are suspicious pelvic masses. Concern-
ing high OV Monitor levels, they could be found in
some cases of benign diseases up to 2000 kU/L and
in some cases of cancer other than of ovarian origin
up to 5000 kU/L. However, if there are suspicious
pelvic masses and OV Monitor concentrations are
)300 kU/L the presence of ovarian cancer seems to
be very probable (Figure 6).
Sensitivity for cancer disease In addition to the com-
parison of the absolute concentrations of both meth-
ods in various patient groups with benign and
malignant diseases, the diagnostic capacity of the
Access OV Monitor (CA125 antigen) assay on the
UniCel DxI 800 Immunoassay System was tested by
ROC curves showing the profile of sensitivity and
specificity over the whole range of values and was
compared to that of CA125 assay on the Elecsys 2010
Immunology System. According to the guidelines of
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Figure 3 Method comparison of the OV Monitor with the reference method.
Correlation of Access OV Monitor (Beckman Coulter) and Elecsys CA125 (Roche Diagnostics) concentrations were calculated
(A) for the range -500 kU/L and (B) for the range -100 kU/L. (C) Normalized differences from mean values were calculated
according to Bland and Altman.
Figure 4 Value distribution of the OV Monitor and reference method in controls.
(d) Dot plot of Access OV Monitor (Beckman Coulter) and (e) Elecsys CA125 (Roche Diagnostics) concentrations in serum
samples of healthy individuals and individuals with various benign diseases.
the European Group on Tumor Markers (EGTM), all
cancer types were compared with the respective
benign disorders as the relevant control group.
Concerning their diagnostic capacity, both methods
showed very comparable results for all cancer types
investigated. This good diagnostic correlation was
expressed by the similar values for the AUC with
overlapping confidence intervals, as well as by the
sensitivity for cancer detection at the 95% specificity
of benign diseases (Table 2). Among all cancers, ovar-
ian cancer showed the highest AUC value for both
methods when compared with benign gynecological
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Table 1 OV Monitor concentrations in sera of cancer patients and controls.
Diagnosis n Method Median, Range, 95th percentile,
kU/L kU/L kU/L
Healthy individuals 267 Dxl 800 9.7 1.3–175.0 30.8
Elecsys 10.7 1.6–158.0 32.7
Benign gynecological diseases 109 Dxl 800 16.4 3.7–276.0 130.0
Elecsys 16.1 1.2–371.0 101.6
Benign breast diseases 148 Dxl 800 12.0 3.5–150.0 44.2
Elecsys 13.7 2.5–310.0 55.9
Benign gastrointestinal diseases 155 Dxl 800 15.4 2.9–1126.0 355.0
Elecsys 17.1 3.4–897.0 232.8
Benign lung diseases 44 Dxl 800 11.7 3.2–111.2 65.1
Elecsys 13.7 4.9–93.2 52.5
Benign urological diseases 66 Dxl 800 15.7 4.0–763.5 121.8
Elecsys 18.2 5.9–590.0 117.1
Other benign diseases 27 Dxl 800 10.9 3.6–247.1 217.1
Elecsys 12.0 4.3–160.0 140.8
Ovarian cancer 81 Dxl 800 445.0 5.2–15,019 4664
Elecsys 305.5 5.0–9908 4266
Gynecological cancer 57 Dxl 800 26.4 4.5–2625 1698
Elecsys 27.0 5.0–1784 979.2
Breast cancer 416 Dxl 800 14.2 2.4–2110 242.7
Elecsys 17.5 2.6–1843 225.6
Gastric cancer 26 Dxl 800 14.2 3.2–83.0 70.9
Elecsys 15.4 4.0–72.0 62.9
Hepatocellular cancer 58 Dxl 800 31.3 4.5–2806 1582
Elecsys 29.9 4.6–2203 1187
Pancreatic cancer 62 Dxl 800 40.3 6.2–1064 623.8
Elecsys 37.9 6.0–669.0 622.2
Colorectal cancer 113 Dxl 800 15.2 3.4–2814 275.9
Elecsys 16.9 4.1–2653 221.3
Lung cancer 82 Dxl 800 30.4 3.4–3496 538.8
Elecsys 29.1 4.0–1904 460.3
Bladder and renal cancer 57 Dxl 800 12.4 3.4–66.9 53.4
Elecsys 13.8 3.3–64.0 53.0
Prostate cancer 43 Dxl 800 12.8 4.0–189.6 152.9
Elecsys 15.7 4.3–151.0 129.7
Median, range and 95th percentile limit of the Access OV Monitor (Beckman Coulter) for healthy individuals, patients with
benign and malignant diseases. Comparison with Elecsys CA125 (Roche Diagnostics) concentrations.
Figure 5 Value distribution of the OV Monitor and reference method in cancer patients.
(d) Dot plot of Access OV Monitor (Beckman Coulter) and (e) Elecsys CA125 (Roche Diagnostics) concentrations in serum
samples of individuals with various malignant diseases.
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Figure 6 Frequency distribution of OV Monitor concentrations in various patient groups.
Frequency of Access OV Monitor values in serum samples of healthy individuals, individuals with various benign diseases,
individuals with various malignant diseases without ovarian cancer, individuals with ovarian cancer without distant meta-
stases (M0) and individuals with ovarian cancer with distant metastases (M1).
Table 2 Diagnostic capacity of OV Monitor for various cancer diseases.
Diagnosis n Method Sensitivity at 95% AUC Confidence
specificity vs. respective Interval
benign diseases
Ovarian cancer 81 Dxl 800 74.1 0.898 0.848–0.949
Elecsys 75.3 0.899 0.850–0.949
Gynecological cancer 57 Dxl 800 21.1 0.587 0.487–0.688
Elecsys 24.6 0.622 0.526–0.718
Breast cancer 416 Dxl 800 16.8 0.573 0.523–0.624
Elecsys 14.7 0.575 0.524–0.626
Gastric cancer 26 Dxl 800 0.0 0.464 0.357–0.571
Elecsys 0.0 0.476 0.367–0.585
Hepatocellular cancer 58 Dxl 800 12.1 0.659 0.579–0.738
Elecsys 12.1 0.652 0.570–0.734
Pancreatic cancer 62 Dxl 800 11.3 0.681 0.602–0.760
Elecsys 12.9 0.680 0.599–0.761
Colorectal cancer 113 Dxl 800 4.4 0.520 0.450–0.589
Elecsys 6.2 0.531 0.462–0.601
Lung cancer 82 Dxl 800 35.4 0.733 0.645–0.821
Elecsys 35.4 0.693 0.601–0.786
Bladder and renal cancer 57 Dxl 800 0.0 0.399 0.299–0.499
Elecsys 0.0 0.387 0.287–0.487
Survey on the diagnostic capacity of the Access OV Monitor (Beckman Coulter) for various cancer diseases when compared
with their respective benign diseases as control groups and comparison with the Elecsys CA125 (Roche Diagnostics). Area
under the curve (AUC) of the receiver operating characteristic curves and sensitivity at 95% specificity vs. the respective
benign diseases indicate the discriminating power.
diseases (Access OV Monitor: AUC 0.898, Elecsys
CA125: AUC 0.899) and the highest sensitivity at 95%
specificity of benign gynecological diseases (Access
OV Monitor: sensitivity 74.1%, Elecsys CA125: sensi-
tivity 75.3%) (Figure 7, Table 2). For ovarian cancer
with distant metastases, the discrimination was even
better with an AUC of 0.931 for the Access OV Monitor
and an AUC of 0.930 for the Elecsys CA125. However,
the Access OV Monitor and Elecsys CA125, respec-
tively, showed diagnostic power for other cancers,
such as lung and gynecological cancers, too. It is
noteworthy to mention that the diagnostic sensitivity
was highest in the adenocellular histological subtype,
whereas it was considerably lower in the squamous
cellular subtype for both gynecological and lung
cancers. Because in lung cancer, CA125 may aid in
finding the histological differential diagnosis, the dif-
ferences are shown in Figure 8. In adeno cell lung
cancer, the AUC reached 0.781 for the Access OV
Monitor and 0.773 for the Elecsys CA125, whereas in
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Figure 7 Diagnostic capacity of the OV Monitor and refer-
ence method for detection of ovarian cancer.
Profiles of sensitivity and specificity over the whole range of
cut-off values are shown by receiver operating characteristic
(ROC) curves for ovarian cancer (ns81) vs. benign gyneco-
logical diseases (ns109). (d) Access OV Monitor (Beckman
Coulter) and (e) Elecsys CA125 (Roche Diagnostics).
squamous cell lung cancer it was only 0.587 for the
Access OV Monitor and 0.546 for the Elecsys CA125
(Figure 8).
Discussion
Several studies have shown that CA125 is the marker
of first choice for diagnosis of ovarian cancer (2, 9,
12–17). However, specificity of CA125 is limited by
various benign diseases, particularly those affecting
the visceral epithelia, e.g., when pleural, pericardial
or peritoneal effusions are present (10, 11). Besides
diagnosis, CA125 levels have shown to be relevant for
the prognosis of ovarian cancer patients undergoing
surgery and/or receiving systemic chemotherapy
(17–19). Similarly, the usefulness of CA125 for thera-
py monitoring, as well as early detection of disease
progression in ovarian cancer patients is widely rec-
ognized and accepted (2, 9, 20–22). In addition to
ovarian cancer, CA125 is detected in endometrial, cer-
vical, lung, renal and gastrointestinal cancer tissues,
as well as in the serum of these patients (2, 9, 24–26).
In the present study, the new Access OV Monitor
assay, which uses the monoclonal antibodies OVK95
and OV185 for detection of the CA125 antigen (23),
was tested on its analytical and clinical performance.
The guidelines of the EGTM (27) require a new diag-
nostic method to be investigated for potential influ-
ence of organ-specific and non-specific influences
which might alter the metabolism of the antigen. Fur-
ther, the new method has to be compared with a cur-
rent accepted method to demonstrate its superiority,
or at least equivalence, for the intended indication.
First, we therefore performed a thorough analytical
evaluation at five European centers, to test the basic
preconditions for routine application. Then, a large
panel of sera from 1811 individuals was investigated.
These individuals included healthy individuals,
patients with gastrointestinal and other benign dis-
eases and many patients with various cancer diseases
that might be relevant for differential diagnosis by
CA125. The entire clinical evaluation of the Access OV
Monitor was carried out in parallel with the Elecsys
CA125, a current standard method, using the same
sera from the same patients, to enable a fair compar-
ison of both methods.
The analytical performance for the OV Monitor
assay was very good with a low within-run, total
and inter-laboratory imprecision. Additionally, we
observed high recoveries during linearity upon dilu-
tion testing, and no high-dose hook effect up to
27,193 kU/L. Sample type interference studies dem-
onstrated that serum and lithium-heparinate plasma
can be used interchangeably. However, OV Monitor
levels in EDTA plasma and citrate plasma were
approximately 10%–20% lower than in serum. Con-
cerning sample storage, it is important to note that
freezing did not affect the marker values, and long-
term storage for 6 months at –208C still yielded stable
results. Of clinical relevance is the finding that endog-
enous interferents, such as hemoglobin, bilirubin,
triglycerides and rheumatoid factor, do not influence
OV Monitor concentrations.
Comparison of the Access OV Monitor with Elecsys
CA125 showed an excellent correlation for all patients
and for the various subgroups investigated. This
observation is all the more valuable as the slope and
intercept were only minimal, meaning that the abso-
lute values of both methods were very comparable.
Nevertheless, it has to be pointed out that in single
patients considerable differences in the concentra-
tions were observed showing the necessity to plan
carefully the potential change of the CA125 antigen
methods and to measure CA125 antigen in parallel
with both methods if kinetic interpretations are car-
ried out.
In our study, healthy individuals had very low con-
centrations, as measured with both methods. Cut-offs
for the URLs were very comparable and were in the
range of the values indicated by both methods (Beck-
man Coulter: 35 kU/L, Roche Diagnostics: 35 kU/L).
Concentrations in sera of individuals diagnosed
with benign gastrointestinal, lung, breast, gynecolog-
ical diseases and other disorders were higher than in
healthy individuals. The differences were only slight
in benign lung and breast diseases, whereas single
individuals with benign gastrointestinal, gynecologi-
cal and urological diseases reached higher values. As
expected, the highest CA125 levels were observed in
benign gastrointestinal diseases, which were affected
with peritoneal effusion. In this group, the median
level was in the range of other benign diseases, but
single individuals reached extremely high levels
()1000 kU/L).
CA125 concentrations in patients suffering from
various cancers were also elevated. However, in
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Figure 8 Diagnostic capacity of the OV Monitor and reference method for detection of other gynecological cancers and lung
cancer.
Profiles of sensitivity and specificity over the whole range of cut-off values are shown by receiver operating characteristic
(ROC) curves for (A) gynecological cancers (ns57) vs. benign gynecological diseases (ns109), (B) adeno cell lung cancer
(ns29) vs. benign lung diseases (ns44), (C) squamous cell lung cancer (ns13) vs. benign lung diseases (ns44), and
(D) small cell lung cancer (ns21) vs. benign lung diseases (ns44). (d) Access OV Monitor (Beckman Coulter) and (e) Elecsys
CA125 (Roche Diagnostics).
some cancer types, the medians and 95th percentiles
were comparable with those of benign diseases, e.g.,
for bladder, renal and prostate cancer. In contrast,
gastrointestinal, gynecological and lung cancers dem-
onstrated greater CA125 elevations, which reached
)1000 kU/L in some patients.
However, it has to be pointed out that most of the
samples of healthy individuals, and individuals with
various benign diseases and individuals with malig-
nant diseases without ovarian cancer had very low
OV Monitor levels not only in the reference range
-35 kU/L but even below 15 kU/L. In contrast, only a
few individuals with ovarian cancer with or without
distant metastases had such low OV Monitor concen-
trations suggesting that the non-release of CA125
antigen is essential to estimate the probability of not
having ovarian cancer if there are suspicious pelvic
masses. On the contrary, even if high CA125 antigen
levels were found in some individuals with benign
diseases or cancer other than of ovarian origin, CA125
antigen levels )300 kU/L and suspicious pelvic mass-
es are very suggestive for ovarian cancer with or with-
out distant metastases.
As expected, the best diagnostic accuracy of the OV
Monitor for cancer detection against the relevant
benign control group was found for ovarian cancer
(AUC: 0.898, sensitivity at 95% specificity vs. benign
gynecological controls 74.1%). This excellent differ-
ential diagnostic result cannot be achieved by other
established tumor-associated antigens and underlines
the high relevance of CA125 antigen in ovarian can-
cer. Importantly, OV Monitor results also correspond
very well with the diagnostic accuracy of the CA125
reference method for cancer detection, demonstrated
by the similar AUC values and the broadly overlap-
ping confidence intervals. Though the diagnostic
power of the OV Monitor is lower for other tumor
types, it has to be emphasized that for lung and gyne-
cological cancer the AUC was still higher than or near
to 0.6 and the sensitivity at 95% specificity vs. the rel-
evant benign control group was higher than 20% –
once again, both methods were very comparable. As
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already mentioned by some previous reports (26), the
diagnostic sensitivity of CA125 antigen was highest in
the adenocellular histological subtype, whereas it was
considerably lower in the squamous cellular subtype
for both gynecological and lung cancers. This diag-
nostic performance in cancer types for which CA125
was not considered as a relevant marker suggests
there may be value in including CA125 with other
diagnostically relevant markers in future multipara-
metric analyses. In combination with well-known
markers, e.g., CYFRA 21-1, carcino-embryonic anti-
gen, neuron-specific enolase and squamous cancer
cell antigen in lung cancer, CA125 might be helpful to
further improve the diagnostic accuracy and may aid
in finding the histological differential diagnosis (26,
28).
Conclusions
The Access OV Monitor is a new assay based on an
alternative antibody for CA125 antigen detection. The
Access OV Monitor provides very good methodolog-
ical characteristics for use in routine laboratory and
demonstrates an excellent analytical and clinical cor-
relation with the Elecsys CA125. The OV Monitor
shows a high diagnostic accuracy in ovarian cancer
and it is a valuable marker in the management of this
disease. Our results also suggest a clinical value of
the OV Monitor in lung and gynecological cancers. If
the CA125 antigen method is changed, parallel meas-
urements of CA125 with both methods for an appro-
priate time span are strongly recommended.
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